Rachel Phillips
Family · Athens, GANPI 1609395946
Payments from drug & device makers
Across 322 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$1K
- Boehringer Ingelheim$880
- AstraZeneca$791
- GSK$657
- Grifols USA, LLC$504
- Actelion Pharmaceuticals US, Inc.$435
- plus $3K from 27 others
What the payments were for
- Travel & lodging$99713%
- Food & beverage$6,36185%
- Education$1031%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 9 | $1,320 |
| Boehringer Ingelheim | 34 | $880 |
| AstraZeneca(2 entities) | 48 | $791 |
| GSK | 43 | $657 |
| Grifols USA, LLC | 24 | $504 |
| Actelion Pharmaceuticals US, Inc. | 22 | $435 |
| Mylan Specialty L.p. | 20 | $317 |
| Sanofi | 12 | $307 |
| Harmony Biosciences LLC | 13 | $277 |
| Mallinckrodt Hospital Products Inc. | 8 | $215 |
| Insmed, Inc. | 8 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $187 |
| Merck | 8 | $184 |
| Regeneron Healthcare Solutions, Inc. | 7 | $163 |
| United Therapeutics Corporation | 8 | $161 |
| Bayer | 8 | $153 |
| Baxter Healthcare | 5 | $111 |
| AbbVie | 5 | $86 |
| Viatris Specialty LLC | 5 | $75 |
| Johnson & Johnson | 4 | $55 |
| Inogen, Inc. | 4 | $50 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $35 |
| Advanced Respiratory, Inc | 2 | $34 |
| Amgen | 2 | $34 |
| Optinose US, Inc. | 1 | $24 |
| Liquidia Technologies, Inc. | 1 | $24 |
| Verona Pharma, Inc. | 1 | $21 |
| Resmed Corp | 1 | $20 |
| Shionogi Inc | 1 | $20 |
| Pfizer | 1 | $15 |
| Electromed, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,461 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 224 | $188,972 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $38,345 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $30,131 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $25,401 |
| EliquisApixaban | 23 | $15,509 |
| SymbicortBudesonide/Formoterol Fumarate | 54 | $14,309 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $14,204 |
| Spiriva RespimatTiotropium Bromide | 14 | $12,549 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 189 | $6,096 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $3,653 |
| Wixela InhubFluticasone Propion/Salmeterol | 27 | $1,612 |
| Fluticasone Propionate | 64 | $779 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 13 | $738 |
| Azelastine Hcl | 19 | $651 |
| Ipratropium Bromide | 16 | $528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $657 | $252,718339 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $791 | $44,440101 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $880 | $26,75339 claims |
| PfizerEliquis | $15 | $15,50923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Athens
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.